Animal Models of Human Disease 3.0

Topic Information

Dear Colleagues,

The use of animal models of human disease is critical for furthering our understanding of fundamental disease mechanisms, for the discovery of novel treatment targets, and for effective translational research. This Topic aims to collect state-of-the-art primary research studies, Communications and Review articles from international experts and leading groups using animal models to study human diseases. Submissions are welcome on a wide range of animal models and pathologies, including infectious disease, acute injury, regeneration, cancer, autoimmunity, and degenerative and chronic disease. We are interested in studies on traditional laboratory animal models, as well as on other comparative small or large animal models, including wild animal models, or animals which show unusual regenerative, metabolic, immune, or age-related properties, or adaptions to survival in extreme environments.

Prof. Dr. Sigrun Lange
Prof. Dr. Jameel M. Inal
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cells cells	5.1	9.9	2012	17 Days	CHF 2700	Submit
International Journal of Molecular Sciences ijms	4.9	8.1	2000	16.8 Days	CHF 2900	Submit
Metabolites metabolites	3.5	5.7	2011	16.1 Days	CHF 2700	Submit
Physiologia physiologia	-	-	2021	19.6 Days	CHF 1000	Submit
Life life	3.2	4.3	2011	17.8 Days	CHF 2600	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Cells IJMS Metabolites Physiologia Life

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 219 KiB)

20 pages, 4923 KiB  

Open AccessArticle

Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor

by Ki Yeon Kim, Ji Min Lee, Eun Ji Lee, Daun Jung, Ah-Ra Goh, Min Chul Choi, Sang Geun Jung, Hyun Park, Sohyun Hwang, Haeyoun Kang and Hee Jung An

Cells 2025, 14(5), 325; https://doi.org/10.3390/cells14050325 - 21 Feb 2025

Viewed by 534

Abstract

Patient-derived xenograft (PDX) models are powerful tools in cancer research, offering an accurate platform for evaluating cancer treatment efficacy and predicting responsiveness. However, these models necessitate surgical techniques for tumor tissue transplantation and face challenges with non-uniform tumor growth among animals. To address [...] Read more.

Patient-derived xenograft (PDX) models are powerful tools in cancer research, offering an accurate platform for evaluating cancer treatment efficacy and predicting responsiveness. However, these models necessitate surgical techniques for tumor tissue transplantation and face challenges with non-uniform tumor growth among animals. To address these issues, we attempted to develop a new PDX modeling method using high-grade serous ovarian cancer (HGSC), a fatal disease with a 5-year survival rate of 29%, which requires personalized research due to its morphological, genetic, and molecular heterogeneities. In this study, we developed a new patient-derived cancer cell xenograft (PDCX) model with high engraftment efficiency (64%) that utilizes primary cancer cells instead of patient tissues. Primary cancer cells can be stably cryopreserved for extended periods (up to 485 days), and when transplanted into female NSGA mice, they maintain morphological and molecular characteristics without significant genetic differences compared to their original primary tumors. Furthermore, PDCX models can be easily produced using a syringe, allowing for uniform tumor sizes across multiple animals. Additionally, M2 PDCXs exhibited a significantly faster growth rate compared to M2 PDTXs. Consequently, our PDCX model offers a streamlined approach for evaluating personalized cancer treatments with minimal experimental variability. Full article

(This article belongs to the Topic Animal Models of Human Disease 3.0)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1